Reply to the letter to the editor 'Number-Needed-To-Treat for pricing costly anti-cancer drugs. The example of Regorafenib in metastatic colorectal cancer' by Graziano et al

Ann Oncol. 2016 May;27(5):958. doi: 10.1093/annonc/mdw049. Epub 2016 Feb 9.

Authors

F Pignatti¹, J Martinalbo², B Jonsson³, P Foggi⁴

Affiliations

¹ Department of Scientific and Regulatory Management francesco.pignatti@ema.europa.eu.
² Human Medicines R&D Support, European Medicines Agency, London, UK.
³ Department of Clinical Evaluation, Swedish Medical Products Agency (MPA), Uppsala, Sweden.
⁴ Department of Authorisation, Italian Medicines Agency (AIFA), Rome, Italy.

PMID: 26861599
DOI: 10.1093/annonc/mdw049

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Agents
Colorectal Neoplasms
Humans
Phenylurea Compounds*
Pyridines*

Substances

Antineoplastic Agents
Phenylurea Compounds
Pyridines
regorafenib